# Who does McKesson Corporation pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/mckesson · Facet: suppliers · Updated: 2026-09-23T09:58:33.590806+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: McKesson Corporation's confirmed suppliers/cost counterparties include Pfizer Inc., Merck & Co., Vertex Pharmaceuticals Incorporated plus 8 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 11 cost edges, backed by 15 dated sources, 10 of them primary filings (as of 2026-09-23).

### Core Ventures (high)
- metric: Amount $2.5B · acquisition completed 2025-06-02 · Cash consideration for a 70% controlling interest in Core Ventures
- note: McKesson acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash in June 2025. The organization supports the business and administrative operations of a Florida oncology practice and joined McKesson's oncology platform.
- [confirms] SEC EDGAR (EN, filing, published 2025-08-06) https://www.sec.gov/Archives/edgar/data/927653/000092765325000107/mck-20250630.htm: "The Company acquired a 70% controlling interest for $2.5 billion in cash."

### 화이자 (high)  → /pfizer.md
- metric: Revenue share 25 percent · FY2025 · Share of Pfizer 2025 total revenue generated from McKesson as a wholesaler customer
- note: McKesson purchases pharmaceuticals as one of Pfizer's U.S. wholesaler customers. Pfizer's reverse disclosure shows that McKesson generated 25% of Pfizer's 2025 total revenue; this is not McKesson's supplier-spend share.
- [confirms] Pfizer Inc. (EN, filing, published 2026-02-26) https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/2025-Form-10-K.pdf: "McKesson, Inc. 25%."

### 머크 (미국 MSD) (high)  → /merck-co.md
- metric: receivables share 22 percent · 2025-12-31 · Share of Merck total accounts receivable attributable to McKesson at year-end 2025
- note: McKesson is a wholesaler customer that purchases Merck products. Merck's reverse disclosure attributes about 22% of its year-end 2025 accounts receivable to McKesson; this is not McKesson's supplier-spend share.
- [confirms] Merck & Co., Inc. (EN, filing, published 2026-02-24) https://www.merck.com/wp-content/uploads/sites/124/2026/02/MRK-12.31.2025-10K-FINAL.pdf: "McKesson Corporation represented approximately 22% of total accounts receivable at December 31, 2025."

### 버텍스 파마슈티컬스 (high)  → /vertex-pharmaceuticals.md
- note: McKesson is Vertex's largest disclosed customer and accounted for 22% of Vertex's total gross product revenues in FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm: "McKesson Corporation 22%."

### 길리어드 사이언스 (high)  → /gilead-sciences.md
- note: McKesson and its specialty distributor affiliates are major U.S. wholesale customers of Gilead and represented 24% of Gilead's total gross product sales in FY2025.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm: "McKesson Corporation 24%."

### 암젠 (high)  → /amgen.md
- note: McKesson, the largest U.S. drug wholesaler and Amgen's single biggest channel, accounted for 34% of Amgen's total gross revenues in FY2025 ($26.25B gross product sales).
- [confirms] SEC EDGAR (EN, filing, published 2026-02-13) https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm: "Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenues."

### 일라이 릴리 (high)  → /lilly-eli.md
- note: McKesson serves as a direct channel for Lilly's revenue by purchasing Lilly products, and Lilly's 10-K discloses that each of the three U.S. wholesalers (McKesson, Cencora, and Cardinal) accounts for 10%+ of consolidated revenue, with Lilly selling to these wholesalers rather than pharmacies, making its concentration on McKesson as the largest U.S. wholesaler both a source of channel bargaining power and the layer where the gross-to-net gap (rebates, PBMs) forms.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm: "Three U.S. wholesalers (McKesson, Cencora, Cardinal) each 10%+ of consolidated revenue"

### 브리스톨 마이어스 스퀴브 (high)  → /bristol-myers-squibb.md
- note: McKesson is BMS's largest U.S. pharmaceutical wholesale customer, with gross revenue to McKesson representing 36% of BMS's U.S. gross revenue in 2025, up from 34% in 2024.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-11) https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm: "McKesson Corporation | 36% | 34% | 33%."
- [confirms] SEC EDGAR (EN, filing, published 2025-02-12) https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm: "McKesson Corporation | 34% | 33% | 32%."

### 덱스콤 (high)  → /dexcom.md
- note: McKesson, a U.S. pharmaceutical distributor for Dexcom whose relationship Dexcom disclosed generated at least 10% of FY2022 revenue, continued to be listed as an authorized distributor for retail G6 and G7 products in 2026.
- [confirms] Dexcom (EN, ir, published 2026-09-23) https://www.dexcom.com/en-us/dexcom-suppliers: "McKesson Corporation – US Pharmaceutical | Retail."
- [mentions] Grand View Research (EN, research, published 2026-09-01) https://www.grandviewresearch.com/industry-analysis/continuous-glucose-monitoring-market: "The pharmacies segment led the market with the largest revenue share of 59.4% in 2025."
- [confirms] SEC EDGAR (EN, filing, published 2023-02-09) https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm-20221231.htm: "McKesson, our most significant wholesalers and distributors, each generated 10% or more of our total revenue."

### 바이오젠 (high)  → /biogen.md
- note: McKesson was a major U.S. wholesale distributor for Biogen and accounted for more than 10% of Biogen's total revenue and 27% of its gross product revenue in FY2014.
- [confirms] SEC EDGAR (EN, filing, published 2015-02-04) https://www.sec.gov/Archives/edgar/data/875045/000087504515000005/biib-20141231x10k.htm: "AmerisourceBergen and McKesson each accounted for more than 10% of our total revenues in 2014."

### 존슨앤드존슨 (mid)  → /johnson-johnson.md
- note: McKesson is an authorized U.S. wholesaler for J&J Innovative Medicine, and although J&J disclosed that three wholesalers handled a substantial share of FY2025 gross revenue, it did not map the percentages to names, so no McKesson-specific amount is assigned.
- [confirms] Janssen Pharmaceuticals, Inc. (EN, ir, published 2024-09-26) https://www.jnj.com/innovativemedicine/us/authorized-distributors-policies: "MCKESSON CORPORATION. Wholesale/Distributor."
- [mentions] Morningstar Equity Research (EN, analysis, published 2024-04-30) https://www.morningstar.com/content/cs-assets/v3/assets/blt9415ea4cc4157833/blt94f5075298dc8306/66202cc046f75c49a44437cd/U.S._Drug_Distribution_Landscape.pdf: "Cardinal Health, Cencora, and McKesson have 95% of the overall US drug distribution market."

### 벡톤 디킨슨 (mid)  → /becton-dickinson.md
- note: McKesson is a major independent distributor supplying BD products to U.S. healthcare providers, while BD revenue attributable to McKesson is not disclosed.
- [confirms] U.S. Court of Appeals for the Seventh Circuit via Justia (EN, analysis, published 2022-03-18) https://law.justia.com/cases/federal/appellate-courts/ca7/21-1513/21-1513-2022-03-18.html: "Cardinal and McKesson are two of the largest distributors of the Products."

Reverse side: https://valuechain.wiki/mckesson/customers.md · Ripple: https://valuechain.wiki/mckesson/ripple.md

---
Full node: https://valuechain.wiki/mckesson.md · JSON: https://valuechain.wiki/mckesson.json